The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 19, 2023

Filed:

Jun. 25, 2019
Applicant:

Chang Gung University, Taoyuan, TW;

Inventors:

Hsin-Pai Li, Taoyuan, TW;

Cheng-Lung Hsu, Taoyuan, TW;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); C12Q 1/6886 (2018.01); G16H 50/30 (2018.01); G16B 20/10 (2019.01); G16B 40/10 (2019.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); G16B 20/10 (2019.02); G16B 40/10 (2019.02); G16H 50/30 (2018.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01);
Abstract

The disclosure provides a method for evaluating whether an individual with cancer is suitable for being administered with anti-cancer drugs. Wherein the anti-cancer drug is a CDK inhibitor. The method includes the following steps: (1) detecting a copy number of a first gene and a copy number of a second gene from an in vitro sample of the individual with the cancer to obtain a copy number variation (CNV) of the first gene and a copy number variation (CNV) of the second gene; (2) calculating a copy number variation ratio (CNV ratio) between the copy number variation (CNV) of the first gene and the copy number variation (CNV) of the second gene, wherein the first gene encodes a cyclin and the second gene encodes a cyclin dependent kinase inhibitor (CDKN); and (3) determining whether the individual with the cancer is suitable for being administered with the CDK inhibitor according to the CNV ratio.


Find Patent Forward Citations

Loading…